Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and partnerships with big pharma are some of the other topics the former AstraZeneca executive discussed.
The US biotech segment is adjusting to a new normal when it comes to the funding environment, with some firms becoming “increasingly sensitive” about how they slow their burn rate or get best value.
While that belt-tightening may have a trickledown effect in the short term on the fortunes of contract research, development and...